Lung Cancer Europe shared a post on LinkedIn:
“Radioligand therapy is a growing area of cancer research – including in lung cancer.
It uses a radioactive drug to find and destroy cancer cells from the inside. The “ligand” targets the tumour. The radioactive part delivers a controlled dose of radiation.
It’s already used in prostate and neuroendocrine cancers. Now it’s being studied in small cell lung cancer, especially where a protein called DLL3 is present.
It’s not widely available yet, but research is moving fast. This could offer a new targeted option where few others exist.”
More posts featuring Lung Cancer Europe.